The neurobiology and pharmacotherapy of Alzheimer's disease

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 11, Issue 1, 1999, Pages 19-31

  Felician, Olivier ^a   Sandson, Thomas A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ESTROGEN; TAU PROTEIN;

ALZHEIMER DISEASE; HUMAN; NERVE DEGENERATION; NEUROBIOLOGY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032907474     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.11.1.19     Document Type: Review

References (142)

1. Tomlinson BE, Blessed G, Roth M: Observations on the brains of demented people. J Neurol Sci 1970; 11:205-242
2. Alzheimer A: Uber eine eigenartige Erkrankung der Hirnrinde. Zeitschrift für Psychiatrie 1906; 10:146-148
3. Maurer K, Volk S, Gerbaldo H: Auguste D and Alzheimer's disease. Lancet 1997; 349:1546-1549
4. Amaducci L: Alzheimer's original patient (letter). Science 1996; 274:328
5. Glenner GG, Wong CW: Alzheimer's disease: report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120:885-890
6. Selkoe DJ: Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996; 271:18295-18298
7. Mann DMA, Esiri MM: The pattern of acquisition of plaques and tangles in the brain of patients under 50 years of age with Down's syndrome. J Neurol Sci 1989; 89:169-179
8. Jarret JT, Berger EP, Lansbury PT: The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32:4693-4697
9. Dekosky ST: Advances in the biology of Alzheimer's disease, in The Dementias: Diagnosis, Management, and Research, 2nd edition, edited by Weiner MF. Washington, DC, American Psychiatric Press, 1996, pp 313-330
10. Bugiani O, Tagliavini F, Giaccone G, et al: Diffuse senile plaques: amorphous or fibrous. Am J Pathol 1995; 146:777-778
11. Ohtsubo K, Izumiyama N, Shimada H, et al: Three-dimensional structure of Alzheimer's neurofibrillary tangles of the aged human brain revealed by the quick-freeze, deep-etch and replica method. Acta Neuropathol 1990; 79:480-485
12. Pearson RCA, Esiri MM, Hiorns RW, et al: Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 1985; 82:4531-4534
13. Terry RD, Peck A, DeTeresa R, et al: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10:184-192
14. Giannakopoulos P, Hof PR, Giannakopoulos A, et al: Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch Neurol 1995; 52:1150-1159
15. Arriagada PV, Growdon JH, Hedley-Whyte T, et al: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42:631-639
16. Khachaturian ZS: Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42:1097-1104
17. Mirra SS, Heyman A, McKeel D, et al: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-486
18. Esch FS, Keim PS, Beattie EC, et al: Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990; 248:1122-1124
19. Nitsch RN, Slack BE, Wurtman RJ, et al: Release of Alzheimer amyloid. Science 1992; 258:304-307
20. Caporaso GL, Gandy SE, Buxbaum JD, et al: Protein phosphorylation regulates secretion of Alzheimer beta A4 amyloid precursor protein. Proc Natl Acad Sci USA 1992; 89:3055-3059
21. Haass C, Koo EH, Mellon A, et al: Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992; 357:500-503
22. Golde TE, Estus S, Younkin LH, et al: Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 1992; 255:728-730
23. Koo EH, Squazzo SL: Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 1994; 269:17386-17389
24. Querfurth HW, Selkoe DJ: Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry 1994; 33:4550-4561
25. Goldgaber D, Lerman MI, McBride OW, et al: Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987; 235:877-880
26. St George Hislop PH, Tanzi RE, Polinsky RJ, et al: The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987; 235:885-890
27. Patterson D, Gardiner K, Kao FT, et al: Mapping of the gene encoding the beta-amyloid precursor protein and its relationship to the Down syndrome region of chromosome 21. Proc Natl Acad Sci USA 1988; 85:8266-8270
28. Goate A, Chartier-Harlin MC, Mulan M, et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704-706
29. Murrell J, Farlow M, Ghetti B, et al: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991; 254:97-99
30. Chartier-Harlin M, Crawford F, Houlden H, et al: Early onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353:844-846
31. Mullan M, Houlden H, Windelspecht M, et al: A locus for familial early onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat Genet 1992; 2:340-342
32. Hendriks L, Van Dujn CM, Cras P, et al: Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992; 1:218-221
33. Citron M, Vigo-Pelfrey C, Teplow DB, et al: Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer's disease mutation. Proc Natl Acad Sci USA 1994; 91:11993-11997
34. Scheuner D, Eckman C, Jensen M, et al: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2:864-870
35. Hsiao K, Chapman P, Nilsen S, et al: Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 1996; 274:99-102
36. Nalbantoglu J, Tirado-Santiago G, Lahsaini A, et al: Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 1997; 387:500-505
37. Games D, Adams D, Alessandrini R, et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373:523-527
38. Shellenberg GD, Bird TD, Wijsman EM, et al: Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258:668-671
39. Sherrington R, Rogaev EI, Liang Y, et al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375:754-760
40. Sandbrink R, Zhang D, Schaeffer S, et al: Missense mutations of the PS-1/S182 gene in German early-onset Alzheimer's disease patients. Ann Neurol 1996; 2:265-266
41. Rogaev EI, Sherrington R, Rogaeva EA, et al: Familial Alzheimer disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer disease type 3 gene. Nature 1995; 376:775-778
42. Levy-Lahad E, Wasco W, Poorkaj P, et al: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269:973-977
43. Kovacs DM, Fausett HJ, Page KJ, et al: Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 1996; 2:864-870
44. Cook DG, Sung JC, Golde TE, et al: Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites. Proc Natl Acad Sci USA 1996; 93:9223-9228
45. De Strooper B, Saftig P, Craessaerts K, et al: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391:387-390
46. Wisniewski T, Palha JA, Ghiso J, et al: S182 protein in Alzheimer's disease neuritic plaques. Lancet 1995; 346:1366
47. Giannakopoulos P, Bouras C, Kovari E, et al: Presenilin-1-immunoreactive neurons are preserved in late-onset Alzheimer's disease. Am J Pathol 1997; 150:429-136
48. Lemere CA, Lopera F, Kosik KS, et al: The E280A presenilin 1 Alzheimer mutation produces increased Abeta 42 deposition and severe cerebellar pathology. Nat Med 1996; 2:1146-1150
49. Corder EH, Saunders AM, Strittmatter WJ, et al: Gene dose of Apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923
50. Saunders AM, Strittmatter WJ, Schmechel D, et al: Association of apolipoprotein E allele epsilon4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472
51. Mahley RW: Apolipoprotein E: cholesterol transport protein with expending role in cell biology. Science 1988; 240:622-630
52. Nalbantoglu J, Gilfix BM, Bertrand P, et al: Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol 1994; 36:889-895
53. Corder EH, Saunders AM, Risch NH, et al: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease. Nat Genet 1994; 7:180-184
54. Hyman BT, Gomez-Isla T, Briggs M, et al: Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996; 40:55-66
55. Blacker D, Haines JL, Rodes L, et al: ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997; 48:139-147
56. Roses AD, Strittmatter WJ, Pericak-Vance MA, et al: Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet 1994; 343:1564-1565
57. Schmechel DE, Saunders AM, Strittmatter WJ, et al: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90:9649-9653
58. Strittmatter WJ, Saunders AM, Schmechel D, et al: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad 1993; 90:1977-1981
59. Strittmatter WJ, Weisgraber KH, Huang DY, et al: Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer's disease. Proc Natl Acad 1993; 90:8098-8102
60. Evans KC, Berger EP, Cho CG, et al: Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 1995; 92:763-767
61. Ma J, Yee A, Brewer B Jr, et al: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994; 372:92-94
62. Strittmatter WJ, Saunders AM, Goedert M, et al: Isoformspecific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer's disease. Proc Natl Acad Sci USA 1994; 91:11183-11186
63. Roses AD, Einstein G, Gilbert J, et al: Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Ann NY Acad Sci 1996; 777:146-157
64. Nathan BP, Chang KC, Bellosta S, et al: The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microlubule depolymerisation. J Biol Chem 1995; 270:19791-19799
65. Mahley RW, Nathan BP, Pitas RE: Apolipoprotein E: structure, function, and possible roles in Alzheimer's disease. Ann NY Acad Sci 1996; 777:139-145
66. Yankner BA, Duffy LK, Kirschner DA: Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990; 250:279-282
67. Lorenzo A, Yankner B: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994; 91:12243-12247
68. Loo DT, Copani A, Pike CJ, et al: Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 1993; 90:7951-7955
69. Busciglio J, Lorenzo A, Yeh J, et al: Beta amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995; 14:879-888
70. Terry RT: The pathogenesis of Alzheimer's disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996; 55:1023-1025
71. Sohal RS, Weindruch R: Oxidative stress, caloric restriction, and aging. Science 1996; 273:59-63
72. Smith CD, Carney JM, Starke-Reed PE, et al: Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proc Natl Acad Sci USA 1991; 88:10540-10543
73. Subbarao KV, Richardson JS, Ang LC: Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990; 55:342-345
74. Pappolla MA, Omar RA, Kim KS, et al: Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am J Pathol 1992; 140:621-628
75. 2+ homeostasis and cell death. J Neurosci 1995; 15:6239-6249
76. Mattson MP, Rydel RE: Amyloid ox-tox transducers. Nature 1996; 382:674-675
77. Disterhoft JF, Moyer JR Jr, Thompson LT: The calcium rationale in aging and Alzheimer's disease. Ann NY Acad Sci 1994; 747:382-106
78. Fritze J, Walden J: Clinical findings with nimodipine in dementia: test of the calcium hypothesis. J Neural Transm 1995; 46(suppl):439-453
79. Yan SD, Chen X, Fu J, et al: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382:685-691
80. Hori O, Brett J, Slattery T, et al: The receptor for advance glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 1995; 270:25752-25761
81. Sano M, Ernesto C, Thomas RG, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336:1216-1222
82. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364
83. Schneider LS, Tariot PN, Goldstein B: Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 1994; 56:750-756
84. Freedman M, Rewilak D, Xerri T, et al: L-deprenyl in Alzheimer's disease. Neurology 1998; 50:660-668
85. Riekkinen P, Koivisto K, Helkala E, et al: Long-term double-blind trial of selegiline in Alzheimer's disease. Neurobiol Aging 1996; 15(suppl 1):S67
86. Burke WJ, Roccaforte WH, Wengel SP, et al: L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41:1219-1225
87. Dysken MW, Mendels J, LeWitt P, et al: Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 1992; 40:503-506
88. Orgogozo JM, Dartigues JF, Lafont S, et al: Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997; 153:185-192
89. Maxwell S, Cruickshank A, Thorpe G: Red wine and antioxidant activity in serum. Lancet 1994; 344:193-194
90. Le Bars PL, Katz MM, Berman N, et al: A placebo-controlled, . double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA 1997; 278:1327-1332
91. Pappolla MA, Sos M, Omar RA, et al: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17:1683-1690
92. Mishima K, Okawa M, Hishikawa Y, et al: Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994; 89:1-7
93. Tohgi H, Abe T, Takahashi S: Concentration of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci Lett 1992; 141:9-12
94. McGeer PL, McGeer E, Rogers J, et al: Anti-inflammatory drugs and Alzheimer's disease. Lancet 1990; 335:1037
95. McGeer PL, McGeer EG: Complement proteins and complement inhibitors in Alzheimer's disease. Res Immunol 1992; 143:621-624
96. Rogers J, Schultz J, Brachova L, et al: Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res Immunol 1992; 143:624-630
97. Aisen PS, Davis KL: Inflammatory mechanisms in Alzheimer's disease: implication for therapy. Am J Psychiatry 1994; 151:1105-1113
98. Wyss-Coray T, Masliah E, Mallory M, et al: Amyloidogenic role of cytokine TGF-beta 1 in transgenic mice and in Alzheimer's disease. Nature 1997; 389:603-606
99. Payami H, Schellenberg GD, Zareparsi S, et al: Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 1997; 49:512-518
100. Jenkinson ML, Bliss MR, Brain AT, et al: Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989; 28:86-88
101. Breitner JCS, Gau BA, Welsh KA, et al: Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44:227-232
102. Andersen K, Launer LJ, Ott A, et al: Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 1995; 45:1441-1445
103. Stewart WF, Kawas C, Corrada M, et al: Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48:626-632
104. Rich JB, Rasmusson DX, Folstein MF, et al: Nonsteroidal antiinflammatory drugs in Alzheimer's disease. Neurology 1995; 45:51-55
105. Rogers J, Kirby LC, Hempelman SR, et al: Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43:1609-1611
106. Aisen PS, Davis KL: The search for disease-modifying treatment for Alzheimer's disease. Neurology 1997; 48(suppl 6):S35-S41
107. MacKenzie IRA: Antiinflammatory drugs in the treatment of Alzheimer's disease. J Rheumatol 1996; 23:806-808
108. El Khoury J, Hickman SE, Thomas CA, et al: Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996; 382:716-719
109. Pericak-Vance MA, Bass MP, Yamaoka LH, et al: Complete genomic screen in late-onset familial Alzheimer's disease. JAMA 1997; 278:1237:1241
110. Kamboh MI, Sanghera DK, Ferrel RE, et al: Apo-E4 associated Alzheimer's disease risk is modified by alpha-1-antichymotrypsin polymorphism. Nat Genet 1995; 10:486-488
111. Kang DE, Saitoh T, Chen X, et al: Genetic association of the low-density lipoprotein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997; 49:56-61
112. Simpkins JW, Singh M, Bishop J: The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging 1994; 15(suppl 2):S195-S197
113. Henderson VW, Paganini-Hill A, Emanuel CK, et al: Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994; 51:896-900
114. Mortel KF, Meyer JS: Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995; 7:334-337
115. Tang MX, Jacobs D, Stern Y, et al: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432
116. Kawas C, Resnick S, Morrison A, et al: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48:1517-1521
117. Schneider LS, Farlow MR, Henderson VW, et al: Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 46:1580-1584
118. Kesner RP: Reevaluation of the contribution of the basal forebrain cholinergic system to memory. Neurobiol Aging 1988; 9:609-616
119. Cummings JL, Kaufer D: Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47:876-883
120. Bowen DM, Smith CB, White P, et al: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99:459-496
121. Dekosky ST, Scheff SW, Markesbery WR: Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging. Neurology 1985; 35:1425-1431
122. Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease (letter). Lancet 1976; 2:1403
123. Whitehouse PJ, Price DL, Struble RG, et al: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215:1237-1239
124. Perry EK, Tomlinson BE, Blessed G, et al: Correlations of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2:1457-1459
125. Francis PT, Palmer AM, Sims NR, et al: Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N Engl J Med 1985; 313:7-11
126. Sims NR, Bowen DM, Smith CCT, et al: Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1980; 1:333-336
127. Wallace WC, Lieberburg I, Schenk D, et al: Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. J Neurosci 1995; 15:4896-4905
128. Stern RG, Davis KL: Research in treating cognitive impairment in Alzheimer's disease, in The Dementias: Diagnosis, Management, and Research, 2nd edition, edited by Weiner MF. Washington, DC, American Psychiatric Press, 1996, pp 331-353
129. Bodick NC, Offen WW, Levey AI, et al: Effects of xanomeline, a selective muscarinic receptor agonist,' on cognitive function and behavioral symptoms of Alzheimer's disease. Arch Neurol 1997; 54:465-473
130. Davis KL, Mohs RC: Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139:1421-1424
131. Mohs RC, Davis KL: The experimental pharmacology of Alzheimer's disease and related dementias, in Psychopharmacology: The Third Generation of Progress, edited by Meltzer HY, New York, Raven Press, 1987, pp 921-928
132. Summers WK, Majovski LV, Marsh GM, et al: Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315:1241-1245
133. Davis KL, Thal LJ, Gamzu ER, et al: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259
134. Farlow M, Gracon SI, Hershey LA, et al: A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529
135. Knapp MJ, Knopman DS, Solomon PR, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991
136. Knopman D, Schneider L, Davis K, et al: Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47:166-177
137. Watkins PB, Zimmerman HJ, Knapp MJ: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA; 1994:992-998
138. Rogers SL, Friedhoff LT, and the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293-303
139. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145
140. Bondareff W, Mountjoy CQ, Roth M: Loss of neurons of origin of the adrenergic projection to the cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982; 32:164-168
141. Zweig RM, Ross CA, Hedreen JC, et al: The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24:233-242
142. Zubenko GS, Moossy J: Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 1988; 45:1182-1186